NCT02229929.

Trial name or title	A double‐blind, randomized, placebo‐controlled study to evaluate the safety and pharmacokinetics of intravenous CR845 in hemodialysis patients, and its safety and efficacy in hemodialysis patients with uremic pruritus
Methods	Multicentre, randomised, double‐blind, placebo‐controlled, parallel assignment, phase 2
Participants	84 haemodialysis patients
Interventions	Group 1: CR845 (0.5 mcg/kg, 1.0 mcg/kg, 2.5 mcg/kg) Group 2: placebo
Outcomes	Pharmacokinetics of Repeated Doses of CR845 in Haemodialysis Patients (half‐life, Cmax, Tmax, AUC, Vd); change in worst itching intensity using a 100 mm VAS; change in quality‐of‐life assessed using the Skindex‐10 survey; sleep disturbance assessed using itch Medical Outcomes Study (MOS) survey
Starting date	July 2014
Contact information	Stephen Cincotta (scincotta@clinicalresearchmgt.com)
Notes	Completed